

*Citation for published version:*

Baxevanis, F, Kuiper, J & Fotaki, N 2016, 'Fed-state gastric media and drug analysis techniques: Current status and points to consider', *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 107, pp. 234-248.  
<https://doi.org/10.1016/j.ejpb.2016.07.013>

*DOI:*

[10.1016/j.ejpb.2016.07.013](https://doi.org/10.1016/j.ejpb.2016.07.013)

*Publication date:*

2016

*Document Version*

Peer reviewed version

[Link to publication](#)

*Publisher Rights*

CC BY-ND

**University of Bath**

## **Alternative formats**

If you require this document in an alternative format, please contact:  
[openaccess@bath.ac.uk](mailto:openaccess@bath.ac.uk)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Fed-state Gastric Media and Drug Analysis Techniques: Current status and Points to**  
2 **Consider**

3 Fotios Baxevanis<sup>1</sup>, Jesse Kuiper<sup>2</sup>, Nikoletta Fotaki<sup>1\*</sup>

4 <sup>1</sup> Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

5 <sup>2</sup> Analytical Sciences, Merck Research Laboratories, West Point, PA, USA

6

7 Address for correspondence:

8 Dr Nikoletta Fotaki

9 Department of Pharmacy and Pharmacology

10 University of Bath

11 Claverton Down

12 Bath, BA2 7AY

13 United Kingdom

14

15 Tel. +44 1225 386728

16 Fax: +44 1225 386114

17 E-mail: [n.fotaki@bath.ac.uk](mailto:n.fotaki@bath.ac.uk)

18

19

## 1. Introduction

*In vitro* dissolution studies are an integral part of quality control and drug development processes. During drug development, they are used as a tool for the selection of the appropriate excipients and the most suitable formulation type [1] and also as an *in vitro* surrogate for *in vivo* performance [2]. In quality control, they are used to ensure the batch-to-batch consistency. [3-5]. Dissolution tests, as dictated by the Pharmacopoeias though, cannot always provide information about the *in vivo* behaviour of the drugs, even though there are cases in which these tests can provide good *in vitro*–*in vivo* correlations (IVIVC). The dissolution media described in Pharmacopoeia monographs are mainly used for quality control purposes, and are not often able to predict the *in vivo* behaviour of poorly soluble drugs for which the fat content and the bile salts concentration in the gastrointestinal environment will affect their solubility and dissolution rate [6, 7]. Due to the limited ability of the simple aqueous media suggested by the Pharmacopoeias to simulate the characteristics of the gastrointestinal (GI) tract, the need for media simulating the GI physiological environment in the fasted and fed states (usually called biorelevant media) arose; in these media the physicochemical properties of the GI contents (pH, osmolality, surface tension, buffer capacity) are taken into account and physiological components such as bile salts and lecithin are incorporated [2]. Use of biorelevant media during the drug development process enables the assessment of drug's biopharmaceutic characteristics and the prediction of *in vivo* performance [2, 8].

While the fasted state gastric environment has been well studied, the more complex conditions of the fed state stomach have made the prediction of food effect a challenging task. Several *in vitro* biorelevant gastric media have been used for the simulation of the gastric fed state environment and as far as the sample treatment is concerned, there is no specific protocol available and sample treatment and drug analysis are developed on a case by case basis. A good understanding of the *in vivo* conditions of the fed state stomach could lead towards the

development of a suitable medium being able to simulate the gastric content and ideally overcoming the extensive treatment before the analysis that is needed with the current gastric fed state media [9, 10]. The dependence of the drug food effect on the meal content, the role of the fat content in the solubilisation of drugs, the gastric emptying rate and the interaction with certain formulations [11] as well as the binding of drugs with metal ions and meal components are some of the parameters which have rendered the *in vitro* prediction of food effect extremely complicated.

In the current review, initially we describe the available information for the characterisation of the *in vivo* gastric fed state conditions after the administration of standard meals with an aim to provide an understanding of the effect of drug's physicochemical parameters on its *in vivo* behavior. Then, the standard meals and the gastric biorelevant media currently being used and their interaction with drugs of different physicochemical properties are presented. In the last part the analytical techniques used *in vitro* for sample treatment and quantification of the drug along with their challenges are discussed.

## **2. *In vivo* gastric conditions in the fed state**

Gastric conditions in fasted state have been characterised in terms of pH, osmolality, surface tension, buffer capacity and protein content [12-14]. In the fed state though, the determination of absolute values is more complicated than in the fasted state. The food type is an additional factor on top of other parameters responsible for the interindividual variation of the above properties such as the individual's age [15] and administered medication [16]. The role of several physicochemical parameters of the contents of the fed state stomach on drug's dissolution and absorption is reviewed.

## 70                    **2.1. Gastric secretions in the fed state**

71            The main components of the gastric juice are hydrochloric acid (HCl), pepsinogens,  
72    mucus and water; pepsinogen is the inactive form of pepsin, activated by the presence of HCl  
73    [17]. Pepsin content is higher in the fed state stomach than in the fasted state (fasted state values  
74    = 0.11–0.22 mg/mL). Samples of gastric antrum content of twenty healthy volunteers after  
75    administration of Ensure Plus<sup>®</sup>, demonstrated pepsin values within a range from 0.26 to 0.58  
76    mg/mL in a time period from 30 to 210 minutes after administration of the liquid meal [13].  
77    Gastric lipase is also present in the stomach. It is the enzyme responsible for the digestion of  
78    fat in the upper gastrointestinal tract. Its role involves the hydrolysis of exogenously  
79    administered triglycerides to di-glycerides and fatty acids [18]. Gastric lipase is has been  
80    reported to account from 10-30% of the total hydrolysis of triglycerides contained in a meal  
81    [19, 20] with the activity of the enzyme measured at 11.4–43.9 U/mL [21]. Its total output  
82    after administration of a liquid meal was  $22.6 \pm 8.1$  mg (concentration  $16.7 \pm 0.7$  µg/mL) after  
83    administration of a liquid meal in human subjects [19].

## 84                    **2.2. Bile salts in gastric contents in the fed state**

85            Bile salts can increase the dissolution of poorly soluble drugs by decreasing the energy  
86    barrier between the drug and the medium, by increasing the active surface area, or via micellar  
87    solubilisation [22]. Bile salt concentration in the stomach is much smaller than in the small  
88    intestine, where the bile salts are released by the gall bladder, with their concentration in the  
89    intestinal environment in the fasted state demonstrating an approximate 4-fold decreased value  
90    in comparison to the fed state (1-4 mM and 10-20 mM, respectively) [23, 24]. In the gastric  
91    fed state (after administration of 500 mL Ensure Plus<sup>®</sup>) only traces of bile salts have been  
92    reported (60 µM) [13]. Similar bile salts concentration (51 µM) were measured in the fed state

stomach of healthy subjects after a standard lunch (13.5 g protein, 18 g corn oil, and 53 g carbohydrate in 300 mL water) [25].

### **2.3. Proteins, lipids and carbohydrates in gastric contents in the fed state**

The protein, lipid and carbohydrate content in the fed state stomach is dependent on the type of meal consumed before the administration of the drug, therefore their concentration is highly variable and cannot be expressed solely by the results of a single study. Indicatively, the concentrations of proteins and carbohydrates after administration of 500 mL Ensure Plus® to healthy subjects were found to be 23.3 mg/mL and 152.1 mg/mL at 30 min respectively, decreasing to 11.2 mg/mL and 49.1 mg/mL at 210 min after the liquid meal's administration [13].

### **2.4. pH of gastric contents in the fed state**

The pH affects dissolution and absorption of both actively and passively absorbed drugs. The non-ionised fraction of the drug is more efficiently absorbed during passive absorption, while the affinity of the drug carrier for the ionised or non-ionised fraction defines the rate of active absorption [26, 27]. The pH of the stomach in the fed state is significantly higher than in fasted state ( $\text{pH} \approx 1.7$ ) [13, 28] with a wide range of values between 3-7 [1]. The pH increases up to approximately a value of 6.5 after a meal and decreases exponentially reaching a value of 2-2.7, similar to the pH value measured in the fasted state after 3-4 hours. In case of patients suffering from hypochlorhydria/achlorhydria due to pathological conditions (i.e. AIDS; Acquired Immune Deficiency Syndrome) or administered medication ( $\text{H}_2$  receptor antagonists or Proton-Pump Inhibitors), initial fasted pH values are elevated compared to the values mentioned above, reducing the dissolution rate of basic drugs [29, 30]. Thirty minutes

after administration of 500 mL of a nutrient drink (Ensure Plus®), Kalantzi et al. reported a pH value of 6.4 in the gastric aspirates of twenty human subjects (Figure 1) and a decrease of the gastric pH to a value close to the fasted state three and a half hours after the liquid meal's administration [13]. The gradual decrease in gastric pH values is attributed to the induction of secretion of gastric acid after the administration of a meal and to the meal's buffering properties [22]. Another *in vivo* study [21] showed that after administration of a liquid standard meal containing 65% fat, 29.5% carbohydrate and 5% protein, the pH reaches a maximum of 4. A study by Yamaguchi et al. [31], which monitored the gastric pH of human subjects using a Bravo® pH monitoring system, with the aid of a capsule placed on the gastric wall, confirmed also the immediate burst and gradual decrease to the fasted state level pH, with it returning to its initial value 2 hours after the administration of a meal. The subjects of the above study were monitored for 48 hours and did not follow any restriction in their dietary routine. The absolute values of these two studies cannot be compared though, as the subjects of the latter did not follow a specific diet. The time needed for the gastric pH levels to return to the initial values and the pH "peak" value of the fed state are dependent upon the type of standard meal administered during each *in vivo* study, the age of the subject and the experimental protocol followed [32]. For instance, the pH decreases to the fasted state value is faster after the administration of a liquid meal than after a solid meal. Gastric pH mostly affects the dissolution of drugs with a pKa value close to the physiological pH values, as when ionised behave as weak electrolytes with their solubility being increased in comparison to their un-ionised form [27]. Therefore, changes in gastric pH mostly affect weak acids and weak bases with the increased values in the fed state enhancing the dissolution of acids and reducing the dissolution of bases. Gastric pH can also affect drug release. Coatings with pH-dependent disintegration

properties, like enteric coatings which dissolve rapidly in pH values of 4.5-8 [21] may experience different disintegration profiles due to elevated fed pH value.

## **2.5. Osmolality of gastric contents in the fed state**

Osmolality can affect drug's dissolution rate by inducing changes in the swelling behavior of the formulation. Osmolality is linked with water penetration in the formulation; when the difference in osmotic pressure between the inner and outer (GI environment) part of the formulation decreases, water penetration decreases as well, affecting negatively drug release [33]. The gastric fluids in the fed state are slightly hyperosmotic 30 minutes after administration of Ensure Plus<sup>®</sup> (559 mOsm kg<sup>-1</sup>), and their osmolality is decreased to 217 mOsm kg<sup>-1</sup> 3.5 h after the administration [13], revealing that the osmolality of the gastric contents returns to the fasted state value during this time period ( $191 \pm 36$  mOsm kg<sup>-1</sup> based on measurements of 24 healthy subjects) [12].

## **2.6. Surface tension of gastric contents in the fed state**

The surface tension of the fed gastric fluids is lower than the one of an aqueous solution due to the presence of surface tension lowering compounds, such as bile salts entering the stomach through duodenal reflux and acting as surfactants, pepsin and food components [34]. Pepsin is an enzyme produced in the mucosal lining of the stomach and acts as a digestive protein in the gastric environment. Since the lowest surface tension values acquired after the addition of biorelevant concentrations (0.003-0.195 mg/mL) of the enzyme (fasted state) in an acidic solution (pH 1.6, HCl solution with 2 g/L NaCl) were 57 mN/m, it can be assumed that other surfactants are present as well in both fasted and fed state gastric fluids, as their surface



tension value was significantly lower with a value of about 30-31 mN/m in the fed state and 33-43 mN/m in the fasted state [4, 35, 36].

## **2.7. Buffer capacity of gastric contents in the fed state**

The buffer capacity of the medium can have a great effect on drug's dissolution in combination with its pH, as change in pH can affect the ionisation percentage and consequently the solubility of ionisable drugs and excipients. In the fasted state, bicarbonate is the buffer mainly present in the stomach [37]. In the fed state though, the buffer capacity is dependent mainly on the meal contents than on the stomach's mucosa, making this chemical property highly meal-dependent [37]. Buffer capacity at gastric fed state conditions after administration of Ensure Plus<sup>®</sup> is around 14-28 mmol/L·DpH based on *in vivo* measurements [13].

Table 1 summarises the physicochemical properties of the contents of the gastric fed state environment, as measured *in vivo* in human subjects.

## **3. Drug properties that relate to potential food effect**

Food effects can be induced via the direct interaction of drugs, due to their unique physicochemical properties, with food components [38]. Such interactions include formation of insoluble complexes (i.e. tetracyclines and calcium ions) [39], binding to proteins (i.e. phenytoin) [40], or interaction/exchange of drugs with anionic or cationic sites of dietary fibers (i.e. metformin) [41]. In this section the drug properties that can affect drug dissolution and absorption leading to a potential food effect are described.

### 3.1. Ionisation (pKa)

The pKa determines the percentage of a drug's charged/uncharged form under certain pH conditions and affects the solubility of drugs at differing media pH. Solubility and dissolution of weakly acidic drugs is low at the pH of the fasted stomach as they are mostly in their unionised form. At fed state conditions, where the pH is higher, their gastric solubility and dissolution increase with a subsequent effect on their pharmacokinetics [6]. The uncharged state of the drug has a positive effect on membrane permeability, as the fraction of the unionised form of a drug is proportional to its lipophilicity [42]. As far as weakly basic drugs are concerned, their gastric solubility and dissolution is lower due to the higher pH of the stomach in the fed state in comparison to the fasted state. For compounds which are non-ionisable in the gastric environment a gastric fed state dissolution test is essential [6], as the type of meal consumed affects the surface tension of the gastric contents and thus, the active surface area which is available for drug solubility and dissolution [43].

### 3.2. Lipophilicity (log P, log D)

Partition coefficient, log P, is indicative of the lipophilicity of a compound and determines the partition of a compound in a system of n-octanol/water. For an ionisable molecule the apparent partition coefficient (log D) is the value which expresses the partition in the aqueous and organic phase in a more accurate way as it takes into consideration its ionised/unionised percentage and therefore log D values vary according to the pH of the environment. Log P values are related to drug's affinity for biological membranes and target sites affecting its biological activity [42]. Ideally, the drug should have such a hydrophilic-lipophilic balance so that it can be dissolved in the biological fluids, where the site of absorption is, and also be able to permeate the membranes of the site of action. Drug's lipophilicity is believed to have an important role in its dissolution in the gastric fed state, as solubility and

dissolution of lipophilic drugs in the fed stomach is performed through their partitioning in the lipid fraction of the meal during its breaking into particles throughout digestion before reaching the small intestine [6].

### 3.3. Solubility

Solubility is a key drug property for its potential oral absorption. Due to the prolonged residence of the drug in the gastric environment during the fed state, the solubility in the gastric contents will affect drug's dissolution and subsequent absorption. The wetting and solubilisation of drugs co-administered with food can be increased by the digestion products of lipolysis products in the gastrointestinal tract (Figure 2) [22]. The gastric compartment is the part of the gastrointestinal tract where the dietary lipids are emulsified at first place. Facilitated by gastric lipase, gastric agitation and emptying, protein and polysaccharide contents along with lypolytic triglyceride products stabilize the interface between lipid and aqueous phase [18]. Therefore, the presence of gastric lipase in the fed stomach is important when biorelevance need to be achieved for *in vitro* assays. Aqueous media usually give an underestimation of the drugs' solubility in the gastric environment. An underestimation of solubility was also observed for undigested milk, suggesting that apart from having the same pH, buffer capacity, protein content and osmolality, the presence of enzymes should be considered for a good prediction of drug's solubility in the gastric environment [44]. If not adequately soluble in the gastrointestinal fluids, drugs orally administered can have a solubility limited dissolution and non-linear dose responses due to inadequate drug in solution in the site of absorption [42].

### 3.4. Biopharmaceutics Classification system (BCS) and Food effect

Amidon and co-workers [45] defined drug aqueous solubility and permeability as determining parameters which control a drug's systemic *in vivo* absorption and introduced the Biopharmaceutics Classification System (BCS) which categorizes the drugs in four classes according to their aqueous solubility and permeability:

**BCS I compounds:** high solubility-high permeability

**BCS II compounds:** low solubility-high permeability

**BCS III compounds:** high solubility-low permeability

**BCS IV compounds:** low solubility-low permeability

Fleischer et al. [46] proposed a food effect predictive model for the drugs' absorption according to their drugs' BCS class (delayed/no effect for BCS class I, increased with fat content for BCS class II, decreased for BCS class III, low and non-predictable for fed/fasted states for BCS class IV); this model is only a general guideline as many drugs do not follow this pattern. The reason is that except for BCS class I drugs, the drugs belonging to the other BCS classes have a wide range of properties and consequently different rate limiting steps for drug absorption. For example, a low solubility compound with absorption just under 90% is classified as a class IV compound, but it is unlikely that its permeability would be the rate limiting step for its absorption [47]. Based on the BCS classification, Wu and Bennet [48], correlated the interactions of the different BCS class drugs with intestinal efflux and reflux transporters. It was suggested that for BCS class II compounds, the relative magnitude of the inhibition between efflux and influx transporters with additional solubilisation in the intestinal environment and gastric emptying are the two parameters affecting the drugs' absorption, with the latter process being the detrimental one. Inhibition of influx transporters was suggested for

the negative food effect for most BCS class III compounds, while BCS class IV compounds combine all the above mechanisms for BCS class II and III drugs (Table 2) making the prediction of food effect difficult [49].

#### **4. Standard meals used in BA/BE studies**

Homogenised standard meals have been used as an attempt to simulate gastric fed state conditions. In order to determine the effect of food on drug absorption, both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) recommend the use of a high-fat meal for the determination of drug's pharmacokinetic parameters in the fed state as the worst case scenario [50]. Meals which are of a high caloric and fat content are recommended in BA/BE studies as these are more likely to affect gastric physiology and have a more pronounced effect on drugs [51]. As a high-fat and high-calorie meal FDA suggests a meal of 800-1000 caloric content with ~50% of the calories deriving from its fat content with 150, 250 and 500-600 kilocalories (kcal) being obtained by protein, carbohydrate and fat, respectively [51]. An example of a typical high fat standard breakfast as proposed by the FDA used in a bioequivalence study for Cicloral<sup>®</sup> and Neoral<sup>®</sup>, (100 mg cyclosporine A formulations) [52] is: "2 eggs fried in butter, 2 strips of fat bacon, 120 g hash brown potatoes, 250 mL whole milk, and 1 croissant". For food effect studies, EMA suggests a similar standardised high fat meal (800-1000 kcal caloric content, 500-600 and 250 of which derive from fat and carbohydrates, respectively) and a moderate meal of ~400-500 kcal with ~150 kcal deriving from fat [50]. As far as the dosage strength to be tested in fed state studies is concerned, FDA recommends the testing of the highest dose to be marketed and lower doses if the testing of the former is not possible for safety reasons [51]. According to EMA, the highest

and lowest doses in the drug therapeutic range have to be tested when the drug follows nonlinear pharmacokinetics [50].

Apart from the meals described previously, other types of meals can also be used in the investigation of the effect of food in drug's pharmacokinetics in cases of a specific food effect mechanism. For example, a high-protein meal (80 g protein, 52 g carbohydrate, 9 g fat) was used in the investigation of the pharmacokinetics of gabapentin, an anticonvulsant, whose transport through the biological membranes is controlled by System-L, the L-amino acid transport system [53]. Klein et al. [43] characterised two standard meals (GSK high fat-(62%) standard meal and FDA intermediate fat (37%) standard meal), constituted by homogenised eggs, bacon, butter, milk and other ingredients indicative of a median diet (Table 3). The purpose of the study was the comparison of their physicochemical properties with those of the meals, such as milk and nutrient drinks currently being used for the simulation of fed-state conditions in dissolution studies.

## **5. *In vitro* simulation of gastric conditions in the fed state (Biorelevant dissolution media)**

Even though actual homogenised meals are able to simulate gastric state conditions the best, problems in the analysis of the drugs led to the development of alternative approaches [37, 54]. A range of dissolution media have been developed in order to simulate the *in vivo* conditions of the fed state stomach (Table 4). These media were developed with the aim of having the same physicochemical properties with the standard meal recommended by FDA for BA/BE studies [51].

### **5.1. Milk-based media**

## ❖ Milk

Milk started being used as a dissolution medium for gastric fed state simulation about twenty years ago. Machairas et al. successfully used low fat milk (0.75% fat) with a flow injection serial dynamic dialysis technique (FISDD) as a food simulation medium for drug dissolution, for four drugs of different physicochemical properties; salicylamide, acetaminophen, propantheline and nitrofurantoin. Milk was selected as a dissolution medium in this study due to its potential as substrate of the gastric fed conditions and also due to its use as a vehicle in drug delivery systems [55]. Furthermore, its energy content is similar to that of a standard meal administered to the subjects participating in bioavailability/bioequivalence studies [56]. Despite its similarities with the gastric environment in the fed state, the use of milk does not always simulate the gastric fed state ideally. The issues of the use of milk as a dissolution medium relate to its lower values in osmolality ( $285 \pm 2.7 \text{ mOsmol kg}^{-1}$ ) and buffer capacity ( $13.9 \pm 0.2 \text{ mEq pH}^{-1} \text{ L}^{-1}$ ) at  $37^\circ\text{C}$  compared to the standard high-fat breakfast proposed by the FDA ( $771 \pm 10 \text{ mOsmol kg}^{-1}$  and  $30.1 \pm 1.8 \text{ pH}^{-1} \text{ L}^{-1}$ , respectively) [43]. Other issues relate to its higher pH value ( $\text{pH} \approx 6.5$ ) than the equivalent pH of gastric media after a meal ( $5.8 \pm 0.2$  after 50% of gastric emptying after liquid meal administration) [56], and the possible need of supplementary enzyme addition due to the digestion of milk's lipids and proteins taking place *in vivo* [6].

In 1998, Galia et al. [58], assessed the suitability of full fat milk as a biorelevant gastric fed state medium for the evaluation of the dissolution behavior of one BCS class I drug (acetaminophen) and two BCS class II drugs (danazol, mefenamic acid). The results of this study demonstrated that for BCS class I drugs there is a strong dependence between the absorption and the type of formulation, with the interaction between the fed matrix and excipients controlling the absorption rate. Milk's high content in lipids enhances the solubility and dissolution of lipophilic drugs; for instance, release of danazol, a BCS class II drug, in

milk, was substantially higher than in water. Furthermore the pH of milk ( $\text{pH} \approx 6.5$ ) favours the dissolution of weak acids, such as mefenamic acid [58]. Diakidou and co-workers showed that despite milk's similarity in pH and protein contents with human aspirates after administration of a liquid meal, the solubility values of two BCS class II weak bases [dipyridamole ( $\text{pK}_a$  5.7–6.4,  $\log P$  2.7) and ketoconazole ( $\text{pK}_a$ s 2.9, 6.5;  $\log P$  4.4)], were 4.7 and 3.6 times lower in milk (after the addition of pepsin and lipase from *Rhizopus niveus*) than in the gastric fed-state aspirates, respectively [44].

#### ❖ Digested milk

After administration of a meal *in vivo*, digestion takes place. *In vitro* digestion milk models have been used for simulation of the *in vivo* digestion of gastric contents. These *in vitro* milk based models, take into consideration the role, amount and activity of the physiologically existing gastric enzymes in the fed state.

In a milk based medium, HCl, lipase and pepsin have been added [44, 59, 60]. Two models using bovine milk were considered for the simulation of gastric environment. In the first model the dissolution of L-sulpiride, a hydrophilic weak base was studied in milk digested with pepsin and HCl [60], with 4.4 mg of pepsin from hog stomach dissolved in HCl being added every 15 min for a 90 min time period. The dissolution assay was performed in USP Apparatus 2 (100 rpm, 500 mL volume). The second model used milk digested with pepsin/HCl/lipase from *Rhizopus niveus* aiming to simulate the fed gastric environment after food intake [44, 59]. In solubility studies of two lipophilic bases, dipyridamole and ketoconazole, it was shown that milk digested with the HCl solution of pepsin gave a good prediction of the ketoconazole's solubility in human gastric aspirates after administration of 500 mL of Ensure® Plus while a solubility overestimation was observed for dipyridamole.



When milk digested with pepsin/HCl/lipase was used the prediction of the drug's solubility in the gastric aspirates was dependent on the time that the *in vivo* sample was collected [44]. The biorelevance of the addition of lipase in the milk in terms of pH and protein content was shown in a release study of felodipine from an extended release matrix. Gastric pH decreased slower and protein content faster than an identical medium in the absence of lipase, giving pH and protein content values closer to the ones observed *in vivo* [13].

#### ❖ Fed State Simulated Gastric Fluid (FeSSGF)

As an effort to improve the biorelevance of milk as dissolution medium and simulate the postprandial conditions of the gastric tube, a medium called Fed State Simulated Gastric Fluid (FeSSGF) was developed. This medium was developed by Jantratid and his co-workers [37] and is comprised of 3.5% fat milk diluted with acetate buffer. In order to mimic the three phases of gastric digestion with the pH value being 6.4, 5.0 and 3.0 for the early, middle and late phases, respectively, a FeSSGF for each phase was prepared (Table 4) [37]. The pH was adjusted with the use of 0.1 N HCl and NaOH solutions and it was suggested that the “middle” medium reflects in a satisfactory manner the sum of the physiological gastric conditions during meal ingestion. Accepting this compromise, FeSSGF could potentially be used as a universal medium potential for fed-state gastric dissolution [37]. It should be noted though that this medium does not contain any enzymes, so the presence of the gastric pepsin and lipase are not taken into account. As milk in the absence of enzymes can only simulate the gastric fed state condition in its early phase [8], the use of the three “snapshot” media can simulate the intraluminal changes in pH, osmolality and protein contents accurately.

## 5.2. Nutrient drinks/Emulsions

The use of various nutrient drinks and emulsion for parenteral administration have been employed to studies as an attempt to mimic the gastric stomach conditions in the fed-state, as they have similar composition (Table 5) to the standardised meals used in drug food effect studies [6].

Scandishake Mix<sup>®</sup> is a nutrient drink used for the simulation of gastric environment in the fed state. It was used in the form of powder mixed with whole milk with simulated gastric secretions containing lipase and pepsin in a dynamic *in vitro* system (TNO TIM-1), simulating the stomach and small and large intestines' environment. Scandishake mix<sup>®</sup> was used for the simulation of a high-fat meal in the development of a dissolution model for fosamprenavir (prodrug of the antiretroviral aprenavir) [61]. Food-induced disintegration of fosamprenavir's tablets was assessed using Magnetic Resonance Imaging (MRI). The stomach compartment in the dynamic system was comprised of two units separated by a silicon wall with the surface between the outer and inner tubes being thermostated (37 °C). The simulated gastric contents were mixed by application of water pressure to the walls, causing three “contractions” and “relaxations” per minute. Simulated gastric lipase and pepsin were pumped to the compartment at a flow of 0.5 mL/min. The nutrient drink, compared with simulated gastric fluid (SGF), which was used for the gastric fasted state simulation, predicted the formulations' proprandial delay in disintegration observed *in vivo*. This effect on the tablet's disintegration can be attributed to the competition of the nutrient drink with the water molecules for the interaction with the matrix and by the formation of a water layer of increased viscosity around the tablet [61].

The nutrient drinks Ensure<sup>®</sup> [62] and Ensure Plus<sup>®</sup> [13, 62] have been used in several studies as biorelevant fed-state gastric media. According to the manufacturer [63], both

emulsions contain water, corn maltodextrin, sugar, milk protein concentrate, canola oil and corn oil (Ensure<sup>®</sup> Plus) or soy oil and sucromalt (Ensure<sup>®</sup>). Intralipid<sup>®</sup>, an emulsion for of similar fat content with Ensure<sup>®</sup> and Ensure Plus<sup>®</sup>, has also been used for the simulation of gastric fed state conditions after the administration of a high-fat breakfast [10]. Ensure<sup>®</sup> contains fat (3.7%), protein (3.7%) and carbohydrate (14.5%), while Intralipid<sup>®</sup> is available in 10, 20 and 30% fat concentrations (soya oil), with the emulsion also containing egg lecithin protein (12 g/1000 mL) and glycerol (22, 22 and 16.7 g/1000 mL for 10, 20 and 30% fat, respectively). Ensure<sup>®</sup> and Intralipid<sup>®</sup> 10% were used at a 1:6 dilution with universal buffer (pH 2.5 and 5.6) in dissolution (USP Apparatus 2, 100 rpm) and microcalorimetry studies of aminophylline controlled release tablets comprised of an aliphatic alcohol and hydroxyalkylcellulose [68]. Each dissolution profile was the expression of two distinct processes; dissolution of the alcohol and diffusion of the drug through the cellulose derivative. The profile was comprised of two first order rates separated by a mixed rate. The composition of the biorelevant medium mainly affected the rate of the initial first-order process and also the onset time of the second apparent first order, indicating that differences in the medium can affect the drug release mechanism.

The similarities of the physicochemical properties (pH, osmolality, buffer, capacity, viscosity and surface tension) between standard meals used in *in vivo* studies and gastric fed state media used *in vitro* have been assessed [43]. Ensure Plus<sup>®</sup> demonstrated better resemblance to the gastric conditions after the administration of a homogenized standard breakfast than milk and Ensure<sup>®</sup> but had significantly different viscosity, an issue resolved after addition of 0.45% w/v pectin, a water soluble polysaccharide. *In vitro* dissolution studies performed with Ensure<sup>®</sup> (USP Apparatus 2) [62] and Ensure Plus<sup>®</sup> [64] (USP Apparatus 3) demonstrated that dissolution behavior is greatly affected by interaction between medium component and formulation. In the above studies, food effect observed *in vitro* was attributed

to a formation of a hydrophobic layer around the formulation (HPMC matrix) decreasing water ingress in the tablet [64], or by granting a more effective hydration of a matrix component [62].

Another nutrient drink, Nutrison<sup>®</sup>, was used for the simulation of gastric fed state conditions in dissolution studies (USP Apparatus 2, 100 rpm) for the study of possible food-drug interactions between food components and metoprolol tartrate IR tablets [5]. The nutrient drink contains 6 g/100 mL protein, 6 g/100 mL vegetable oil fat, 18 g/100 mL carbohydrate, vitamins and minerals. For its use as a biorelevant medium it was diluted to 60% with a solution containing HCl, NaCl, KCl and sucrose, giving values of pH (pH= 5.4) and osmolality (420 mOsm/kg) similar to the *in vivo* fed state conditions. A potential excipient dependent mechanism of delay in tablet disintegration was indicated through the formation of a protein film from the medium's components around the tablets (visual observation) attributed to electrostatic or hydrophobic interactions between the proteins and the excipient confirmed by scanning electron microscopy (SEM). The dependence of the formation of this layer on certain tablet excipients was confirmed by preparation of single excipient-medium mixtures and observation of a precipitation layer in the vessel for each mixture. The effect of meal type was further evaluated by comparing tablet disintegration times in media containing a single (protein, fat or carbohydrate) or mixtures of the mentioned components present in the fed state medium. The presence of proteins increased the tablet disintegration time the most, with a more profound effect when proteins were combined with fat, carbohydrates or both.

Even though the composition of nutrient drinks like Ensure Plus<sup>®</sup> is more similar to the high-fat meals administered in BA/BE studies, milk based media can simulate the fed gastric content taking the presence of secretions into consideration [65]. Moreover, with the two approaches mentioned before (gradual digestion and snapshot media), the changes in the fed gastric environment during time can be more closely simulated.

Another version of the FeSSGF “snapshot” media has been recently proposed replacing milk with Lipofundin® MCT 20, [66] an emulsion administered parenterally to patients, providing essential fatty acids. The emulsion: buffer ratios were different to those of the milk based FeSSGF “snapshot media” (17.5, 8.75 and 4.375% v/v content for early, middle and late media, respectively compared to 100, 50 and 25% for the milk-based media). Lipofundin® does not contain any proteins, which facilitates the drug’s analysis in the medium and has similar fat content to the fed stomach aspirates [67].

## **6. Drug and formulation-related food effect**

Under fed state conditions, tablet disintegration is generally delayed. For example, as mentioned previously, a nutritional drink used both in *in vivo* (canine) and in *in vitro* studies delayed disintegration and dissolution of metoprolol tartrate tablets by creating the formation of a food- induced thin layer around the tablet which not only did prevent the water penetration in the tablet but also the drug particles from leaving the matrix. [5].

Food can have a significant effect on the absorption of drugs. This can be affected by differences in the interaction of the active pharmaceutical ingredient or/and the formulation with the fasted and fed state environments. Examples of two drugs (itraconazole and nifedipine) demonstrating drug-related and formulation-related gastric food effect, respectively, are discussed below.

Itraconazole, an antifungal agent, is a well-studied drug in terms of its food effect. The positive effect of food on itraconazole’s absorption has been verified by both *in vivo* and *in vitro* studies. An *in vivo* study on itraconazole capsules (2 × 100 mg capsules administered) containing sugar coated pellets in healthy subjects was performed with the use of the FDA

standard breakfast for the determination of the drug's food effect [68]. The study showed a significant increase for both  $C_{\max}$  and  $AUC_{0 \rightarrow \infty}$  values ( $C_{\max(\text{fasted})} = 0.59 C_{\max(\text{fed})}$ ,  $AUC_{0 \rightarrow \infty(\text{fasted})} = 0.61 AUC_{0 \rightarrow \infty(\text{fed})}$ ) (Figure 3) with the increase in the drug's absorption being attributed to the drug's increased solubility in the food components. A similar study by Zimmermann et al. [69], (one 100 mg capsule administered with a standard breakfast) demonstrated similar results, with the relative bioavailability in the fasted state being 0.54 times the one observed after meal administration. The differences were attributed to the high-fat content of the meal and also to the longer gastric retention time in the fed state.

*In vitro* studies were in agreement with the fact that the drug's bioavailability could be significantly affected by food [70]. An *in vitro* study used milk of different fat concentrations mixed with simulated gastric fluid (SGF) (pH adjusted to 3) as fed state biorelevant dissolution media and demonstrated that except for fat, other food components may be responsible for the food effect observed with itraconazole *in vitro*. Despite a pronounced difference between dissolution rates in the fasted (SGF pH 3) and the fed state simulated media, the fat content did not lead to statistically significant dissolution rates among the milk-based media. The presence of different carbohydrates (1% w/v glucose, lactose and starch in SGF) increased the dissolution rate at a small extent, possibly by formation of hydrogen bonds between the drug and the carbohydrates' hydroxyl functional groups. On the contrary, increased protein content, appeared to have a positive effect of drug dissolution. Drug dissolution rates in media containing albumin (0.5-4% w/v) concentration in SGF, increased by increasing the protein content. One possible mechanism could be through protein-drug binding possibly by the development of electrostatic and lipophilic interactions between the drug and albumin.

Nifedipine is a calcium channel blocker with a complicated formulation-related food effect [5]. Immediate release tablets, prolonged (modified) release tablets, capsules and soft capsules of nifedipine (5–60 mg) are commercially available [71]. Significant differences in

the bioavailability of nifedipine modified – release formulations after oral administration have been observed *in vivo* between fasted and fed state conditions [72, 73]. The bioavailability of the brand formulation, Adalat OROS® (Osmotic-Release Oral System), has not been significantly affected by the presence of food [72, 74, 75]. Dose dumping and unusually long lag times, possibly due to lack of robustness of the mechanism of drug release in the fed state or due to prolonged stay of the formulation in the stomach, have been observed after administration of generic nifedipine formulations. During the gastric residence of nifedipine, the rate of absorption is limited, which led to rapid and high absorption when it reached the small intestine, altering the formulation's controlled release mechanism characteristics of some generic formulations [76, 77]. Nifedipine Sandoz® retard 30 mg, (eroding matrix system) [74], Nifedipine® 60 mg, (capsule with mini-tablets, Pharmatec International, Milano, Italy) [75], Slofedipine® XL 60 mg (eroding matrix system) [72] and Nifedipine ER 90 mg test tablet (hydrophilic matrix, pilot formulation, Astra AB, Sweden,) [78] demonstrated a formulation induced food effect after co-administration with a high-fat standard breakfast. Nifedipine Sandoz® retard demonstrated significant differences in its pharmacokinetic behavior between fasted and fed states, possibly due to the inability of the matrix to release the drug in a controlled way, with the exact mechanism not having been experimentally proven [76]. Dose dumping and a three-fold increase of the  $C_{max}$  was observed for Nifedipine® under the fed state conditions compared to the fasted state [75]. Slofedipine® XL's profiles between the fasted and the fed state (high-fat breakfast) were also significantly different. Nevertheless, even though the geometric  $AUC_{0 \rightarrow 24}$  mean in the fed state was approximately half the one in the fasted state for Slofedipine® XL, the  $AUC_{0 \rightarrow t_n}$  values were identical [72]. Similar behavior was observed with Nifedipine ER tablets (90 mg), which demonstrated a higher absorption rate than Procardia® XL (90 mg) (osmotic pull-push system tablet), which was used as a reference

product. The effect was attributed to the increased erosion rate as a result of the gastric motility and alterations in the gastric content after meal administration [78].

It is worth mentioning that in several of the above studies, differences in the fed state-pharmacokinetic behavior between the brand and generic formulations have also been observed. In the case of nifedipine Sandoz<sup>®</sup> retard, great inter-patient variability often accompanied with fast, uncontrolled drug release was observed in plasma concentration vs time profiles, demonstrating failure of the controlled release behavior of the formulation under fed conditions [74]. In case of Slofedipine<sup>®</sup> XL [72], the authors concluded that the differences between the test (Slofedipine<sup>®</sup> XL) and the reference (Adalat<sup>®</sup> OROS) formulations in the fed state could be attributed to the prolonged transit time of the former. Slofedipine<sup>®</sup> XL had a significant delay on the onset of its therapeutic action in 15 out of 24 patients of the study (15h lag time), which resulted in 29% decreased  $AUC_{0 \rightarrow t_n}$  compared to Adalat<sup>®</sup>. Slofedipine<sup>®</sup> XL's lag time was attributed to the fact that undissolved particles of the formulation of a diameter above 10 mm were not able to pass through the pylorus, until the onset of phase III of the migrating motor complex (MMC; the cylindrical series of gastric electrical activity, taking place between meals) [79]. In the same study, *in vitro* dissolution studies in acetate buffer pH 4.5 demonstrated that at pH values similar to the fed state, the generic formulation remained undissolved for 24 hours, in contrast to Adalat<sup>®</sup> OROS which was almost 100% dissolved.

## **7. Meal– related food effect**

Drug food effect relates to the nature of the meal. Meal characteristics such as fat content, viscosity, caloric content size, and volume are parameters which can affect its absorption.



550 Increased fat content in the fed state relates to delayed drug absorption due to slower gastric  
551 emptying rate [23] and to decreased drug dissolution due to retarded wetting of the formulation  
552 [80]. Increased viscosity of the gastric contents due to the administered meal delays the rate of  
553 gastric emptying [81]. Increased meal viscosity can decrease the diffusion coefficient of a  
554 compound according to Stokes-Einstein equation [82], which could in turn decrease drug  
555 absorption if it is only absorbed in a specific part of the gastrointestinal tract, as the drug goes  
556 past this site. The effect of meal viscosity is impaired in the small intestine due to secretions  
557 and digestion products. The most common effect of high meal viscosity is an increase in the  
558  $T_{\max}$  values of drugs. In an *in vivo* study using canine subjects, when a calorie free viscosity  
559 enhancer, HPMC (hydroxypropylmethylcellulose), was added, a delay in the  $T_{\max}$  of the  
560 antiarrhythmic bidisomide was observed [83]. The meal's residence time depends also on its  
561 caloric content [26]. 2-4 kcal of caloric content per minute are transferred to the duodenum  
562 [17], meaning that meals with high caloric content will reside in the stomach for longer periods,  
563 affecting drug's transit time in the gastrointestinal tract. Nutrient drinks of 1 kcal/mL content  
564 are emptied at a rate of 2-2.5 mL/min, while nutrient drinks of 0.2 kcal/mL content have an  
565 emptying rate of 10 mL/min [17]. A calorie-dependent decrease of the gastric emptying rate  
566 was observed for the solid portion of the meal ( $45 \pm 3.4\%$  of the meal mass retained in the  
567 stomach for the 68 kcal solid meal and  $65 \pm 4\%$  for the 633 kcal solid meal at 100 min), while  
568 its liquid portion is emptied to the duodenum at a rate independent of its energy content [11].  
569 Meal size and volume relate to its gastric residence time [11]. Meals of fourfold mass and  
570 similar caloric content resulted in a 388% higher emptying rate, attributed to activation of  
571 stretch or volume receptors in stomach, increasing peristalsis. Using different volumes of  
572 isocaloric meals, a statistically significant increase in gastric emptying rate with the larger  
573 volume was noted for volumes of liquid meals between 200 mL and 800 mL [84].

## **8. Analytical techniques and challenges for sample treatment and drug quantification**

Most of the gastric fed state media used until now are milk based or o/w emulsions; therefore, several sample preparation processes have been developed for the extraction of the drugs from these matrices. Milk is a complex biological fluid containing proteins, lipids, carbohydrates, divalent and trivalent cations which can be bound to the compounds of interest making drug analysis challenging. The analytical techniques, issues and challenges described in this section refer mainly to fed state gastric biorelevant media which are at least partly comprised by milk or contain other types of lipid and protein sources. The quantification of drugs in these media is usually performed using high performance liquid chromatography (HPLC) and therefore, the analytical challenges and problems presented below refer mainly to this technique.

### **8.1. Filtration**

The first challenge with drug analysis when biorelevant media are used is filtration itself. Filtration is an essential step in the analytical procedure, as biorelevant media contain a range of particles deriving from lipids, carbohydrates, fat and salts, which have to be removed before the sample's injection in the HPLC. Moreover, when fed biorelevant media like milk or FeSSGF are used, the use of small pore size filters for the sample analysis during solubility or dissolution studies cannot be used due to clogging from the presence of large proteins [9]. Several types of filters like 0.45 or 0.22  $\mu\text{m}$  polytetrafluoroethylene (PTFE) [64] or regenerated cellulose (RC) [44] have been used for sample analysis prior to HPLC injection for drug quantification in both milk and lipid-based media but a sample cleanup step is required before for these type of media. Glass microfiber (GF) 2.7  $\mu\text{m}$  filters have also been used in drug

solubility and dissolution studies in milk based media [85], in order to remove undissolved drug or formulation particles prior to sample treatment and filtration through the filters of smaller pore size. Filters of bigger pore size, attached to the sampling cannulas of the USP Apparatus 1/2 (polyethylene sticks, 10  $\mu$ m and nylon membrane filters, 5  $\mu$ m) have also been used in dissolution studies with FeSSGF and milk for the same reason [56, 85].

Adsorption of the analyte on the filters should be studied in order to evaluate and choose the appropriate filters. Salicylic acid and sodium saccharine are example of drugs which demonstrate significant adsorption on Nylon filters as shown in a study by Carlson et al. [86], where 85.8% and 60.4% of salicylic acid at 0.005 mg/mL and 0.05 mg/mL concentrations respectively was adsorbed on 25 nm nylon filters. Sodium saccharine demonstrated even higher adsorption with the entire drug (100%) being adsorbed on the same filters at a 0.1 mg/mL concentration [86, 87]. It should be noted that if the first few drops of the filtrate are not discarded, the percentage of adsorption can reach extremely high values.

## **8.2. Medium**

The analysis of the drug content in milk based media can be challenging as the content of the medium itself is comprised of a lipid and an aqueous phase that requires separation of the phases before an HPLC analysis can be performed. Analysis could be affected by the differential distribution of the drug in the multiple phases of the milk based media, as it could distribute either in the aqueous or lipid phase or even bind to the proteins or fat contained in the medium. Several drugs have shown binding in milk at amounts higher than 50%; diazepam, indomethacin, griseofulvin and dicumarol demonstrated binding percentages from approximately 55% to 95% in low and full fat milk (37 °C) after equilibrium dialysis against a phosphate buffer solution (pH 6.5). For some drugs, their percentage bound was more significantly affected by milk's temperature (dicumarol, prednisolone) and fat content (e.g.

binding of diazepam increased more than 13% in full fat milk in comparison to low fat milk at temperatures 15–37 °C) [88]. A factor affecting the analysis of milk is its variable fat, carbohydrate and lipid content. Its composition differs among different mammalian species, and is also affected by parameters such as their diet or the onset of their lactation period [89]. Therefore, milk of the same commercial brand and batch should be used when different drugs and dissolution conditions are compared, as changes in the medium composition may affect parameters like recovery, precision, and analytical method compatibility.

### **8.3. Sample treatment and analysis**

#### **i. Protein precipitation**

One simple method of sample cleanup prior to drug quantification in gastric milk- based fed state media is protein precipitation. Protein precipitation is the technique mainly used until now with the addition of a volume of an organic reagent to a volume of medium, followed by a centrifugation and a filtration step before its analysis in HPLC. The precipitation of the milk's proteins can be performed using an organic reagent followed by filtration and centrifugation steps [9].

A range of solvents like acidified MeOH [90], acetone [91] and HCl [92] have been used as protein precipitation reagents for the extraction of drugs from milk-based media. Parameters such as their compatibility with the analytical technique chosen, their volatility in case organic phase evaporation is needed, their selectivity and their cost have to be considered during the selection of an appropriate protein precipitation solvent [88].

Fotaki et al. [60] suggested a precipitation and centrifugation method for the quantification of L-sulpiride, a BSC class III drug, in a milk based dissolution medium,

proposing an assay involving centrifugation at 4000 rpm for 10 min (8 °C) for the separation of the aqueous phase from the lipid phase with acetonitrile being added in the aqueous filtrate (1:2) and a last centrifugation and filtration step (Titan<sup>®</sup> filters 0.45 µm) following. Sample treatment in nutrient drinks and emulsions requires a more time consuming cleanup procedure. Ensure<sup>®</sup> Plus requires phase separation via a centrifugation step (e.g. 11500 rpm, 1.5 h) [64] and possibly an extra filtration step with a larger pore size filter (5 µm) prior to filtering with a 0.45 µm filter and injecting the supernatant in the HPLC.

A study by Williams et al. [10] used 1:2 with ice-cold 12% (w/v) trichloroacetic acid for milk protein precipitation and then centrifugation at 10000 rpm for 15 min extracting 0.2 mL of the supernatant for the HPLC analysis [10] for the quantification of caffeine in both milk-based (0.1%, 1.7%, 3.6% fat milk) and fat emulsion type (30% fat emulsion (Intralipid<sup>®</sup>)) media. Despite the fact that a protein precipitation step, followed by centrifugation and filtration, was adequate for both types of media, the recovery of the drug in the fat emulsion was significantly lower. A challenge associated with the selection of protein precipitation reagents is their compatibility with the HPLC method for the analysis of the selected drug. Peak fronting is a common issue when organic reagents of higher strength than the mobile phase are used; an issue which can usually be resolved with evaporation of the reagent under nitrogen and reconstitution in the mobile phase. Another disadvantage of this technique is its inability of complete removal of the lipid part of the medium [89], as for the selective removal of lipids, a supplementary step is required. This step may be a wash with hexane, given that the compound of interest is ionised or not extracted in hexane, so as not to be lost during the washing step [93].

## **ii. Solid Phase Extraction (SPE)**

Another method used for the extraction of the analyte of interest from milk is Solid Phase Extraction (SPE). Solid phase extraction (SPE) is widely used for the extraction of drugs from biological fluids such as whole blood [94], plasma [95], urine [96] and milk [97], and is often preceded by a protein precipitation step. SPE cartridges are comprised by a polypropylene tube with their sorbent between two porous frits. A typical experimental protocol involves 4 main steps: i. cartridge conditioning, ii. sample loading, iii. sample washing and iv. sample elution [98].

Most cartridges are either comprised of bonded silica phases, similar to the material of the reversed phase HPLC columns but with bigger diameter particles (10–60  $\mu\text{m}$ ), or of polymeric resins (e.g. polystyrene-divinylbenzene). [99] SPE  $\text{C}_{18}$  cartridges have been used for the quantification of several drugs, like  $\beta$ -lactam antibiotics [100] or nonsteroidal anti-inflammatory drugs (NSAIDs) [101], in milk. In the above studies, a protein precipitation step similar to the one previously described [60] took place before the extraction, due to the milk's high content in proteins and lipids, which render the sample too "dirty" to be loaded straight on the cartridge. An elution solvent of high water percentage is preferable for extraction from milk-based media, and has to be able to elute the drug and retain most of the lipids on the cartridge [10]. The extraction yield of lipid drugs using SPE may be low due to the drug's interaction with milk's fat globules. A way to disrupt this drug-fat globule interactions would be sonication and dilution of the medium before its loading on the cartridge [89]. A challenge for the analysis with SPE when it comes to biorelevant media, is the interference from the matrix in HPLC analysis. Therefore, cleanup with a solid phase extraction cartridge can help towards the development of more sensitive and robust methods in drug analysis in fed state biorelevant media. Disadvantages of SPE as a drug's extraction method from gastric fed state media include the quick drying of the cartridges and the difficulty to adjust the vacuum during

the multiple steps without the presence of an automated manifold, affecting the reproducibility of the method [102, 103].

### **iii. Liquid-liquid extraction (LLE)**

Liquid-liquid extraction is based on the analyte partitioning between an aqueous phase and a water-immiscible solvent [99]. Several extraction protocols have been successfully applied for a wide range of drugs such as mycotoxins [104], mycrocyclic lactones [105], vitamins [106] and analgesics [107]. The main advantages of LLE is the short time required for method development and its low cost. A serious drawback is the fact that it is a time-consuming and labour intensive method. Moreover, the possible presence of the milk's lipid content in the extraction solvent after the LLE process, leads to phase separation of the sample and lipid partitioning in the stationary phase of the HPLC column during drug analysis. Therefore a washing step with hexane is usually required, so as to remove the lipids [89], making the whole procedure even more time consuming. The following protocol used in milk for the quantification of Ochratoxin A is a typical case of liquid-liquid extraction [104]; 0.2 mL saturated NaCl solution and 2.4 mL chloroform were added to 1 mL milk, mixed gently for 3 minutes, centrifuged (4500 rpm, 20 minutes) and after the removal of the chloroform layer, evaporation to dryness under nitrogen steam and reconstitution in acetonitrile followed. Lipid removal was performed by double extraction ( $2 \times 0.4$  mL petroleum ether for 1 min). After discarding the etheric layer, acetonitrile was blown to dryness, reconstituted in 1 mL of mobile phase, filtered and analysed in HPLC.

### **iv. Ion Selective Electrode (ISE) sensor**

An online monitoring system, in an attempt to avoid the sample treatment traditionally required for the extraction of the analytes of interest from FeSSGF has been published [9]. An Ion Selective Electrode (ISE) sensor system was used, with two electrodes placed constantly

in the dissolution vessel which were able to monitor the changes in drug concentration through the changes in potential. With this proposed methodology, diphenhydramine hydrochloride was successfully quantified in a dissolution study using the USP Apparatus 2 in several fasted [Fasted State Simulated Gastric Fluid (FaSSGF), Fasted State Simulated Intestinal Fluid (FaSSIF) and Fasted State Simulated Intestinal Fluid Version Two (FaSSIF-V2) and fed (FeSSGF) state biorelevant media. Sample preparation steps needed with extraction techniques were avoided, and a continuous dissolution profile and a much faster and less laborious alternative were offered. Disadvantages of this method are: a. its limitation to the analysis of ionised drugs b. the complicated correction of the baseline needed for the heterogeneous biorelevant media and c. its inability for the analysis of compounds of extremely low aqueous solubility [9].

#### **v. Other techniques**

Several other techniques have been used for drug quantification in milk and may have the potential to be used in fed state gastric media, some of which are briefly listed below:

**Matrix solid-phase dispersion (MSPD):** The matrix solid-phase dispersion (MSPD) technique was firstly developed by Barker et al. [108]. MSPD involves the grinding of biological samples with sorbent particles producing a column material acting as a solid support from which the drugs in the matrix can be selectively extracted [109, 110]. MSPD has been successfully used in drug quantification in milk with sorbents, like C<sub>18</sub> [111], C<sub>8</sub>, silica gel [112], mixed-mode/cationic-exchange (MCX), mixed-mode/anion-exchange (MAX) and weak anion-exchange (WAX) [113], and more recently molecularly imprinted polymers (MIPs) [110]. An advantage of this method is the combination of homogenization, fractionation and



purification in one single step and could be also used to milk-based gastric dissolution media [109]. It is also cheap and environmentally safe but relatively labour demanding [114].

**Solid-phase microextraction (SPME):** SPME is a sample preparation technique which is based on a concentration equilibrium between an extracting phase associated with a solid support and a biological matrix [115]. Two different SPME designs are the most commonly used: in-tube mode and fibre design. In this technique, small quantities of the sorbent are exposed to the headspace or solution of the biological sample using a suitable format. After a predefined amount of time and when equilibrium between the coating and the matrix has been reached, the sorbent does not absorb any additional quantity of the analyte of interest, meaning that the amount of drug extracted for a specific concentration is constant [116]. The main advantages of SPME are its low cost and the fact that it is time saving and environmentally friendly [117]. Some of its disadvantages are the slow time for equilibrium between the analyte and the extraction phase to be reached [118], the poor selectivity and the limited type of fibres commercially available [119].

**Ultrafiltration:** Ultrafiltration is a technique extensively used in food industry and water treatment. It is based on the selective passage of drugs of low molecular weight through the pores of a membrane of a specific MW cut-off, which inhibits the passage of molecules of higher MW. This technique does not involve time-consuming steps but its use is limited by reduced sensitivity due to interferences from the matrix in drug analysis and is usually used in combination with other cleanup techniques [89]. Ultrafiltration was successfully employed for the quantification of tetracyclines in milk, by adding solid EDTA at 10 mM concentration, before sample centrifugation at 5000 rpm for 1 hour. Ultrafree MC/PL devices (nominal molecular weight limit 5000) were used in this study [120].

## 9. Conclusion

Prediction of gastric food-effect of drugs has been a challenge of the pharmaceutical industry. Even though the *in vivo* properties of the fed state gastric environment have been determined in some cases, the complicated fed environment due to differences in the meals administered makes the determination of the precise gastric conditions difficult. Despite the fact that some progress has been made with the development of gastric biorelevant media, a universal robust predictive analytical method has not been yet developed. The development of suitable biorelevant media in combination with a simple and robust analytical method could potentially provide a means of understanding of a potential food effect in regards of a drug's solubility and dissolution. Several biorelevant dissolution fed state media like milk, nutrient drinks or Fed State Simulated Gastric Fluid (FeSSGF) have been developed in an attempt to simulate the human postprandial conditions. Nevertheless, none have managed to achieve precise representation and fully overcome issues such as the need of a time consuming preparation for the quantification of the drug, possible matrix interferences and compatibility with the analytical methods used.

## References

- [1] J.B. Dressman, C. Reppas, G.L. Amidon, V.P. Shah, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, *Pharm. Res.*, 15 (1998) 11-22.
- [2] Q. Wang, N. Fotaki, Y. Mao, Biorelevant dissolution: methodology and application in drug development, *Dissolut. Technol.*, 16 (2009) 6-12.
- [3] A. Simon, V.R. Almeida Borges, L.M. Cabral, V.P. Sousa, Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension, *AAPS PharmSciTech*, 14 (2013) 425-434.
- [4] M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, C. Reppas, Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds, *Eur J. Pharm. Biopharm.*, 60 (2005) 413-417.
- [5] B. Abrahamsson, T. Albery, A. Eriksson, I. Gustafsson, M. Sjöberg, Food effects on tablet disintegration, *Eur. J. Pharm. Sci.*, 22 (2004) 165-172.
- [6] A. Müllertz, Biorelevant dissolution media, in: P. Augustijns, M. Brewster E (Eds.) *Solvent systems and their selection in pharmaceuticals and biopharmaceuticals*, Springer New York, 2007, pp. 151-177.

[7] S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a drug, AAPS J., 12 (2010) 397-406.

[8] N. Fotaki, M. Vertzoni, Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations, TODDJ, 4 (2010) 2-13.

[9] D. Juenemann, H. Bohets, M. Ozdemir, R. de Maesschalck, K. Vanhoutte, K. Peeters, L. Nagels, J.B. Dressman, Online monitoring of dissolution tests using dedicated potentiometric sensors in biorelevant media, Eur. J. Pharm. Biopharm., 78 (2011) 158-165.

[10] H.D. Williams, D.A. Barrett, R. Ward, I.J. Hardy, C.D. Melia, A liquid chromatography method for quantifying caffeine dissolution from pharmaceutical formulations into colloidal, fat-rich media, J. Chromatogr. B., 878 (2010) 1739-1745.

[11] J.G. Moore, P.E. Christian, J.A. Brown, C. Brophy, F. Datz, A. Taylor, N. Alazraki, Influence of meal weight and caloric content on gastric emptying of meals in man, Digest. Dis. Sci, 29 (1984) 513-519.

[12] A. Lindahl, A.L. Ungell, L. Knutson, H. Lennernas, Characterization of fluids from the stomach and proximal jejunum in men and women, Pharm. Res., 14 (1997) 497-502.

[13] L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J. Dressman, C. Reppas, Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res., 23 (2006) 165-176.

832 [14] P.B. Pedersen, P. Vilmann, D. Bar-Shalom, A. Müllertz, S. Baldursdottir, Characterization  
833 of fasted human gastric fluid for relevant rheological parameters and gastric lipase activities,  
834 Eur. J. Pharm. Biopharm., 85 (2013) 958-965.

835

836 [15] S.G. Hughes, Prescribing for the elderly patient: why do we need to exercise caution?, Br.  
837 J. Clin. Pharmacol., 46 (1998) 531-533.

838

839 [16] O. Gursoy, D. Memis, N. Sut, Effect of proton pump inhibitors on gastric juice volume,  
840 gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind,  
841 placebo-controlled study, Clin. Drug Invest., 28 (2008) 777-782.

842

843 [17] F. Kong, R.P. Singh, Disintegration of solid foods in human stomach, J. Food. Sci., 73  
844 (2008) R67-R80.

845

846 [18] C.J.H. Porter, C.W. Pouton, J.F. Cuine, W.N. Charman, Enhancing intestinal drug  
847 solubilisation using lipid-based delivery systems, Adv. Drug Deliver. Rev., 60 (2008) 673-691.

848

849 [19] Carriere F., Barrowman JA., Verger A., R. Laugier, Secretion and contribution to lipolysis  
850 of gastric and pancreatic lipases during a test meal in humans, Gastroenterology, 105 (1993)  
851 876-888.

852

853 [20] Y. Pafumi, D. Lairon, P.L. de la Porte, C. Juhel, J. Storch, M. Hamosh, M. Armand,  
854 Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase, J. Biol. Chem.,  
855 277 (2002) 28070-28079.

856

[21] M. Armand, P. Borel, B. Pasquier, C. Dubois, M. Senft, M. Andre, J. Peyrot, J. Salducci, D. Lairon, Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum, *Am. J. Physiol.*, 271 (1996) G172-183.

[22] W.N. Charman, C.J.H. Porter, S. Mithani, J.B. Dressman, Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH, *J. Pharm. Sci.*, 86 (1997) 269-282.

[23] B. Singh, Effects of Food on Clinical Pharmacokinetics, *Clin. Pharmacokinet.*, 37 (1999) 213-255.

[24] K. Kleberg, J. Jacobsen, A. Müllertz, Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies, *J. Pharm. Pharmacol.*, 62 (2010) 1656-1668.

[25] P. Dewar, R. King, D. Johnston, Bile acid and lysolecithin concentrations in the stomach in patients with duodenal ulcer before operation and after treatment by highly selective vagotomy, partial gastrectomy, or truncal vagotomy and drainage, *Gut*, 23 (1982) 569-577.

[26] J. Dressman, Comparison of canine and human gastrointestinal physiology, *Pharm. Res.*, 3 (1986) 123-131.

[27] D.M. Mudie, G.L. Amidon, G.E. Amidon, Physiological parameters for oral delivery and in vitro testing, *Mol. Pharm.*, 7 (2010) 1388-1405.

882 [28] J. Dressman, R. Berardi, L. Dermentzoglou, T. Russell, S. Schmaltz, J. Barnett, K.  
883 Jarvenpaa, Upper gastrointestinal (GI) pH in young, healthy men and women, *Pharm. Res.*, 7  
884 (1990) 756-761.

885

886 [29] E. L. McConnell, H. M. Fadda, A. W. Basit, Gut instincts: explorations in intestinal  
887 physiology and drug delivery, *Int. J. Pharm.* 364 (2008) 213-226.

888

889 [30] D. Horter, J. B. Dressman, Influence of physicochemical properties on dissolution of drugs  
890 in the gastrointestinal tract, *Adv. Drug Deliv. Rev.*, 46 (2001) 75-87.

891

892 [31] T. Yamaguchi, A. Seza, T. Odaka, T. Shishido, M. Ai, S. Gen, T. Kouzu, H. Saisho,  
893 Placement of the Bravo wireless pH monitoring capsule onto the gastric wall under endoscopic  
894 guidance, *Gastrointest. Endosc.*, 63 (2006) 1046-1050.

895

896 [32] S. Di Maio, R.L. Carrier, Gastrointestinal contents in fasted state and post-lipid ingestion:  
897 In vivo measurements and in vitro models for studying oral drug delivery, *J. Control. Release*,  
898 151 (2011) 110-122.

899

900 [33] M.W. Rudolph, S. Klein, T.E. Beckert, H.-U. Petereit, J.B. Dressman, A new 5-  
901 aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis, *Eur. J. Pharm.*  
902 *Biopharm.*, 51 (2001) 183-190.

903

904 [34] M. Koziolk, G. Koziolk, M. Garbacz, W. Neumann, Weitschies, Simulating the  
905 postprandial stomach: biorelevant test methods for the estimation of intragastric drug  
906 dissolution, *Mol. Pharm.*, 10 (2013) 2211-2221.

907

908 [35] M. Efentakis, J.B. Dressman, Gastric juice as a dissolution medium: surface tension and  
909 pH, *Eur. J. Drug Metab. Pharmacokinet.*, 23 (1998) 97-102.

910

911 [36] B.L. Pedersen, A. Mullertz, H. Brondsted, H.G. Kristensen, A comparison of the solubility  
912 of danazol in human and simulated gastrointestinal fluids, *Pharm. Res.*, 17 (2000) 891-894.

913

914 [37] E. Jantratid, N. Janssen, C. Reppas, J. Dressman, Dissolution media simulating conditions  
915 in the proximal human gastrointestinal tract: An update, *Pharm. Res.*, 25 (2008) 1663-1676.

916

917 [38] P. G. Welling, Effect of food on drug absorption, *Pharmacol. Ther.*, 43 (1989) 425-441.

918

919 [39] H. Jung, A. A. Peregrina, J.M. Rodriguez, R. Moreno-Esparza, The influence of coffee  
920 with milk and tea with milk on the bioavailability of tetracycline, *Biopharm. Drug Dispos.*, 18  
921 (1997) 459-463

922

923 [40] R. Lourenco, Enteral feeding: drug/nutrient interaction, *Clin. Nutr.*, 20 (2001) 187-193.

924

925 [41] H. Gin, M.B. Orgerie, J. Aubertin, The influence of Guar gum on absorption of metformin  
926 from the gut in healthy volunteers, *Horm. Metab. Res.*, 21 (1989) 81-83.

927

928 [42] C.A.S. Bergström, R. Holm, S.A. Jørgensen, S.B.E. Andersson, P. Artursson, S. Beato, A.  
929 Borde, K. Box, M. Brewster, J. Dressman, K.-I. Feng, G. Halbert, E. Kostewicz, M. McAllistar,  
930 U. Muenster, J. Thinner, R. Taylor, A. Mullertz, Early pharmaceutical profiling to predict oral  
931 drug absorption: Current status and unmet needs, *Eur. J. Pharm. Sci.*, (2013).



932

933 [43] S. Klein, J. Butler, J. Hempenstall, C. Reppas, J. Dressman, Media to simulate the  
934 postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts,  
935 J. Pharm. Pharmacol., 56 (2004) 605-610.

936

937

938 [44] A. Diakidou, M. Vertzoni, J. Dressman, C. Reppas, Estimation of intragastric drug  
939 solubility in the fed state: comparison of various media with data in aspirates, Biopharm. Drug  
940 Dispos., 30 (2009) 318-325.

941

942 [45] G. Amidon, H. Lennernäs, V. Shah, J. Crison, A theoretical basis for a biopharmaceutic  
943 drug classification: the correlation of in vitro drug product dissolution and in vivo  
944 bioavailability, Pharm. Res., 12 (1995) 413-420.

945

946 [46] D. Fleisher, C. Li, Y. Zhou, L.-H. Pao, A. Karim, Drug, Meal and Formulation Interactions  
947 Influencing Drug Absorption After Oral Administration, Clin. Pharmacokinet., 36 (1999) 233-  
948 254.

949

950 [47] E. Sjögren, B. Abrahamsson, P. Augustijns, D. Becker, M.B. Bolger, M. Brewster, J.  
951 Brouwers, T. Flanagan, M. Harwood, C. Heinen, R. Holm, H.-P. Juretschke, M. Kubbinga, A.  
952 Lindahl, V. Lukacova, U. Münster, S. Neuhoff, M.A. Nguyen, A.v. Peer, C. Reppas, A.R.  
953 Hodjegan, C. Tannergren, W. Weitschies, C. Wilson, P. Zane, H. Lennernäs, P. Langguth, In  
954 vivo methods for drug absorption – Comparative physiologies, model selection, correlations  
955 with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization  
956 including food effects, Eur. J. Pharm. Sci., 57 (2014) 99-151.

957

958 [48] C.-Y. Wu, L.Z. Benet, Predicting drug disposition via application of BCS:  
959 transport/absorption/elimination interplay and development of a biopharmaceutics drug  
960 disposition classification system, *Pharm. Res.*, 22 (2005) 11-23.

961

962 [49] K. Lentz, M. Quitko, D. Morgan, J. Grace, C. Gleason, P. Marathe, Development and  
963 validation of a preclinical food effect model, *J. Pharm. Sci.*, 96 (2007) 459-472.

964

965 [50] EMA, Guideline on the Investigation of Drug Interactions, European Medicines Agency,  
966 United Kingdom, 2013, pp. 60.

967

968 [51] FDA, Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies,  
969 in, U.S. Department of Health and Human Services Food and Drug Administration Center for  
970 Drug Evaluation and Research (CDER), 2002, pp. 5.

971

972 [52] F. Kees, G. Mair, M. Dittmar, M. Bucher, Cicloral versus neoral: A bioequivalence study  
973 in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral,  
974 *Transplant. Proc.*, 36 (2004) 3234-3238.

975

976 [53] B.E. Gidal, M.M. Maly, J. Budde, G.L. Lensmeyer, M.E. Pitterle, J.C. Jones, Effect of a  
977 high-protein meal on gabapentin pharmacokinetics, *Epilepsy Res.*, 23 (1996) 71-76.

978

979 [54] M. Koziolok, G. Garbacz, M. Neumann, W. Weitschies, Simulating the Postprandial  
980 Stomach: Physiological Considerations for Dissolution and Release Testing, *Mol. Pharm.*, 10  
981 (2013) 1610-1622.

982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005

[55] P. Macheras, M. Koupparis, C. Tsaprounis, Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique, *Int. J. Pharm.*, 33 (1986) 125-136.

[56] L. Kalantzi, B. Polentarutti, T. Albery, D. Laitmer, B. Abrahamsson, J. Dressman, C. Reppas, The delayed dissolution of paracetamol products in the canine fed stomach can be predicted in vitro but it does not affect the onset of plasma levels, *Int. J. Pharm.*, 296 (2005) 87-93.

[57] F. Carrière, C. Renou, V. Lopez, J. de Caro, F. Ferrato, H. Lengsfeld, A. de Caro, R. Laugier, R. Verger, The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals, *Gastroenterology*, 119 (2000) 949-960.

[58] E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, D. Hörter, R. Löbenberg, J.B. Dressman, Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs, *Pharm. Res.*, 15 (1998) 698-705.

[59] A. Diakidou, M. Vertzoni, B. Abrahamsson, J. Dressman, C. Reppas, Simulation of gastric lipolysis and prediction of felodipine release from a matrix tablet in the fed stomach, *Eur. J. Pharm. Sci.*, 37 (2009) 133-140.

[60] N. Fotaki, M. Symillides, C. Reppas, Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration, *Eur. J. Pharm. Sci.*, 26 (2005) 324-333.

1006 [61] J. Brouwers, B. Anneveld, G.-J. Goudappel, G. Duchateau, P. Annaert, P. Augustijns, E.  
1007 Zeijdner, Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro  
1008 evaluation using magnetic resonance imaging and a dynamic gastrointestinal system,  
1009 Eur. J. Pharm. Biopharm., 77 (2011) 313-319.  
1010  
1011 [62] L.J. Ashby, A.E. Beezer, G. Buckton, In vitro dissolution testing of oral controlled release  
1012 preparations in the presence of artificial foodstuffs. I. Exploration of alternative methodology:  
1013 microcalorimetry, Int. J. Pharm., 51 (1989) 245-251.  
1014  
1015 [63] Ensure Products, in, Abbott Laboratories. <https://ensure.com/nutrition-products>, (last  
1016 assessed 2016)  
1017  
1018 [64] F. Franek, P. Holm, F. Larsen, B. Steffansen, Interaction between fed gastric media  
1019 (Ensure Plus®) and different hypromellose based caffeine controlled release tablets:  
1020 Comparison and mechanistic study of caffeine release in fed and fasted media versus water  
1021 using the USP dissolution apparatus 3, Int. J. Pharm., 461 (2014) 419-426.  
1022  
1023 [65] C. Reppas, M. Vertzoni, Biorelevant in-vitro performance testing of orally administered  
1024 dosage forms, J. Pharm. Pharmacol., 64 (2012) 919-930.  
1025  
1026 [66] C. Markopoulos, C.J. Andreas, M. Vertzoni, J. Dressman, C. Reppas, In-vitro simulation  
1027 of luminal conditions for evaluation of performance of oral drug products: Choosing the  
1028 appropriate test media, Eur. J. Pharm. Biopharm., 93 (2015) 173-182.  
1029

1030 [67] M. Armand, P. Borel, C. Dubois, M. Senft, J. Peyrot, J. Salducci, H. Lafont, D. Lairon,  
 1031 Characterization of emulsions and lipolysis of dietary lipids in the human stomach, *Am. J. of*  
 1032 *Physiol.*, 266 (1994) G372-381.

1033

1034 [68] J.A. Barone, J.G. Koh, R.H. Bierman, J.L. Colaizzi, K.A. Swanson, M.C. Gaffar, B.L.  
 1035 Moskovitz, W. Mechlinski, V. Van de Velde, Food interaction and steady-state  
 1036 pharmacokinetics of itraconazole capsules in healthy male volunteers, *Antimicrob. Agents*  
 1037 *Chemother.*, 37 (1993) 778-784.

1038

1039 [69] T. Zimmermann, R.A. Yeates, H. Laufen, G. Pfaff, A. Wildfeuer, Influence of  
 1040 concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole  
 1041 and fluconazole, *Eur. J. Clin. Pharmacol.*, 46 (1994) 147-150.

1042

1043 [70] H.S. Ghazal, A.M. Dyas, J.L. Ford, G.A. Hutcheon, In vitro evaluation of the dissolution  
 1044 behaviour of itraconazole in bio-relevant media, *Int. J. Pharm.*, 366 (2009) 117-123.

1045

1046 [71] MHRA, Medicines Information: SPC & PILs, <http://www.mhra.gov.uk/spc-pil>, (last  
 1047 assessed 2015).

1048

1049 [72] B.S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall, H.H. Blume, The  
 1050 effect of food on the pharmacokinetics of nifedipine in two slow release formulations:  
 1051 pronounced lag-time after a high fat breakfast, *Br. J. Clin. Pharmacol.*, 53 (2002) 582-588.

1052

1053 [73] K. Ueno, S. Kawashima, K. Uemoto, T. Ikada, K. Miyai, K. Wada, K. Yamazaki, K.  
1054 Matsumoto, I. Nakata, Effect of food on nifedipine sustained-release preparation, DICP, 23  
1055 (1989) 662-665.

1056

1057 [74] M. Wonnemann, B. Schug, K. Schmucker, E. Brendel, K. Schmucker, P.A. van Zwieten,  
1058 H. Blume, Significant food interactions observed with a nifedipine modified-release  
1059 formulation marketed in the European Union, Int. J. Clin. Pharm. Th., 44 (2006) 38-48.

1060

1061 [75] B. Schug, E. Brendel, M. Wonnemann, D. Wolf, M. Wargenau, A. Dingler, H. Blume,  
1062 Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation  
1063 after a high-fat American breakfast, Eur. J. Clin. Pharmacol., 58 (2002) 119-125.

1064

1065 [76] D.G. Bailey, J. Malcolm, O. Arnold, J.D. Spence, Grapefruit juice-drug interactions, Br.  
1066 J. Clin. Pharmacol., 46 (1998) 101-110.

1067

1068 [77] C. Wagner, K. Thelen, S. Willmann, A. Selen, J. Dressman, Utilizing in vitro and PBPK  
1069 tools to link ADME characteristics to plasma profiles: case example nifedipine immediate  
1070 release formulation, J. Pharm. Sci., 102 (2013) 3205-3219.

1071

1072 [78] B. Abrahamsson, M. Alpsten, B. Bake, U.E. Jonsson, M. Eriksson-Lepkowska, A.  
1073 Larsson, Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-  
1074 comparison with an osmotic pump tablet and effect of food, J. Control. Release, 52 (1998) 301-  
1075 310.

1076

1077 [79] J. Janssens, G. Vantrappen, T.L. Peeters, The activity front of the migrating motor complex  
 1078 of the human stomach but not of the small intestine is motilin-dependent, *Regul. Peptides*, 6  
 1079 (1983) 363-369  
 1080

1081 [80] P. Macheras, M. Koupparis, S. Antimisiaris, An in vitro model for exploring CR  
 1082 theophylline-milk fat interactions, *Int. J. Pharm.*, 54 (1989) 123-130.  
 1083

1084 [81] L. Marciani, P.A. Gowland, R.C. Spiller, P. Manoj, R.J. Moore, P. Young, S. Al-Sahab,  
 1085 D. Bush, J. Wright, A.J. Fillery-Travis, Gastric response to increased meal viscosity assessed  
 1086 by echo-planar magnetic resonance imaging in humans, *J. Nutr.*, 130 (2000) 122-127.  
 1087

1088 [82] E.A. Mun, C. Hannell, S.E. Rogers, P. Hole, A.C. Williams, V.V. Khutoryanskiy, On the  
 1089 role of specific interactions in the diffusion of nanoparticles in aqueous polymer solutions,  
 1090 *Langmuir*, 30 (2014) 308-317.  
 1091

1092 [83] L.H. Pao, C. Cook, T. Kararli, C. Kirchhoff, S.Y. Zhou, J. Truelove, A. Karim, D. Fleisher,  
 1093 Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-  
 1094 administration: relationship with region-dependent intestinal absorption, *Pharm. Res.*, 15  
 1095 (1998) 221-227  
 1096

1097 [84] M.A. Kwiatak, D. Menne, A. Steingoetter, O. Goetze, Z. Forras-Kaufman, E. Kaufman,  
 1098 H. Fruehauf, P. Boesiger, M. Fried, W. Schwizer, M.R. Fox, Effect of meal volume and calorie  
 1099 load on postprandial gastric function and emptying: studies under physiological conditions by  
 1100 combined fiber-optic pressure measurement and MRI, *Am. J. Physiol. Gastrointest. Liver*  
 1101 *Physiol.*, 297 (2009) G894-G901.

1102

1103 [85] C. Wagner, E. Jantravid, F. Kesisoglou, M. Vertzoni, C. Reppas, J. B. Dressman,

1104 Predicting the oral absorption of a poorly soluble, poorly permeable weak base using

1105 biorelevant dissolution and transfer model tests coupled with a physiologically based

1106 pharmacokinetic model, *Eur. J. Pharm. Biopharm.*, 82 (2012) 127-138.

1107

1108 [86] M. Carlson, R.D. Thompson, Analyte loss due to membrane filter adsorption as

1109 determined by high-performance liquid chromatography, *J. Chromatogr. Sci.*, 38 (2000) 77-

1110 83.

1111

1112 [87] K. Kiehm, J. Dressman, Evaluation of Drug Adsorption to Membrane Filters under

1113 Biowaiver Test Conditions, *Dissolut. Technol.*, 15 (2008) 13-17.

1114

1115 [88] P. Macheras, M. Koupparis, S. Antimisiaris, Drug binding and solubility in milk, *Pharm.*

1116 *Res.*, 7 (1990) 537-541.

1117

1118 [89] D.T. Rossi, D. Scott Wright, Analytical considerations for trace determinations of drugs

1119 in breast milk, *J. Pharmaceut. Biomed.*, 15 (1997) 495-504.

1120

1121 [90] K. Nagy, K. Redeuil, R. Bertholet, H. Steiling, M. Kussmann, Quantification of

1122 anthocyanins and flavonols in milk-based food products by ultra performance liquid

1123 chromatography-tandem mass spectrometry, *Anal. Chem.*, 81 (2009) 6347-6356.

1124

1125 [91] S. Ou, K.C. Kwok, Y. Wang, H. Bao, An improved method to determine SH and –S–S–

1126 group content in soymilk protein, *Food Chem.*, 88 (2004) 317-320.



1127

1128 [92] M.-Y. Pinero, R. Garrido Delgado, R. Bauza, L. Arce, M. Valcarcel, R. Garrido-Delgado,

1129 M. Valcarcel, Easy sample treatment for the determination of enrofloxacin and ciprofloxacin

1130 residues in raw bovine milk by capillary electrophoresis, *Electrophoresis*, 33 (2012) 2978-

1131 2986.

1132

1133 [93] L.A. Dostal, R.P. Weaver, B.A. Schwetz, Excretion of high concentrations of cimetidine

1134 and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic

1135 acid content, *Toxicol. Appl. Pharmacol.*, 102 (1990) 430-442.

1136

1137 [94] L. Zhang, Z.-H. Wang, H. Li, Y. Liu, M. Zhao, Y. Jiang, W.-S. Zhao, Simultaneous

1138 determination of 12 illicit drugs in whole blood and urine by solid phase extraction and UPLC–

1139 MS/MS, *J. Chromatogr. B*, 955–956 (2014) 10-19.

1140

1141 [95] J. Shentu, L. Fu, H. Zhou, X.J. Hu, J. Liu, J. Chen, G. Wu, Determination of amlodipine

1142 in human plasma using automated online solid-phase extraction HPLC–tandem mass

1143 spectrometry: Application to a bioequivalence study of Chinese volunteers, *J. Pharmaceut.*

1144 *Biomed.*, 70 (2012) 614-618.

1145

1146 [96] R. Cazorla-Reyes, J.L. Fernández-Moreno, R. Romero-González, A.G. Frenich, J.L.M.

1147 Vidal, Single solid phase extraction method for the simultaneous analysis of polar and non-

1148 polar pesticides in urine samples by gas chromatography and ultra high pressure liquid

1149 chromatography coupled to tandem mass spectrometry, *Talanta*, 85 (2011) 183-196.

1150

1151 [97] U. Koesukwiwat, S. Jayanta, N. Leepipatpiboon, Solid-phase extraction for multiresidue  
 1152 determination of sulfonamides, tetracyclines, and pyrimethamine in Bovine's milk, J.  
 1153 Chromatogr. A, 1149 (2007) 102-111.

1154

1155 [98] SPE method development, Waters. [http://www.waters.com/waters/en\\_GB/SPE-Method-](http://www.waters.com/waters/en_GB/SPE-Method-Development)  
 1156 [Development](http://www.waters.com/waters/en_GB/SPE-Method-Development) , (last assessed 2016).

1157

1158 [99] C.A. James, Sample Preparation, in: R.F. Venn (Ed.) Principles and Practice of  
 1159 Bioanalysis, Taylor & Francis Group, Boca Raton, US, 2008.

1160

1161 [100] M. Cámara, A. Gallego-Picó, R.M. Garcinuño, P. Fernández-Hernando, J.S. Durand-  
 1162 Alegría, P.J. Sánchez, An HPLC-DAD method for the simultaneous determination of nine  $\beta$ -  
 1163 lactam antibiotics in ewe milk, Food Chem., 141 (2013) 829-834.

1164

1165 [101] P. Gallo, S. Fabbrocino, F. Vinci, M. Fiori, V. Danese, L. Serpe, Confirmatory  
 1166 identification of sixteen non-steroidal anti-inflammatory drug residues in raw milk by liquid  
 1167 chromatography coupled with ion trap mass spectrometry, Rapid Commun. Mass Spectrom.,  
 1168 22 (2008) 841-854.

1169

1170 [102] M. Anastassiades, S.J. Lehotay, D. Stajnbaher, F.J. Schenck, Fast and easy multiresidue  
 1171 method employing acetonitrile extraction/partitioning and "dispersive solid-phase extraction"  
 1172 for the determination of pesticide residues in produce, J. AOAC Int., 86 (2003) 412-431.

1173

1174 [103] S.J. Lehotay, A.R. Lightfield, J.A. Harman-Fetcho, D.J. Donoghue, Analysis of pesticide  
 1175 residues in eggs by direct sample introduction/gas chromatography/tandem mass spectrometry,  
 1176 J. Agric. Food Chem., 49 (2001) 4589-4596.  
 1177

1178 [104] A. Gürbay, G. Girgin, S.A. Sabuncuoğlu, G. Şahin, M. Yurdakök, Ş. Yiğit, G. Tekinalp,  
 1179 Ochratoxin A: is it present in breast milk samples obtained from mothers from Ankara,  
 1180 Turkey?, J. Appl. Toxicol., 30 (2010) 329-333.  
 1181

1182 [105] G. Rübensam, F. Barreto, R.B. Hoff, T.L. Kist, T.M. Pizzolato, A liquid–liquid extraction  
 1183 procedure followed by a low temperature purification step for the analysis of macrocyclic  
 1184 lactones in milk by liquid chromatography–tandem mass spectrometry and fluorescence  
 1185 detection, Anal. Chim. Acta, 705 (2011) 24-29.  
 1186

1187 [106] M. Kašparová, J. Plíšek, D. Solichová, L. Krčmová, B. Kučerová, M. Hronek, P. Solich,  
 1188 Rapid sample preparation procedure for determination of retinol and  $\alpha$ -tocopherol in human  
 1189 breast milk, Talanta, 93 (2012) 147-152.  
 1190

1191 [107] V. Kmetec, R. Roškar, HPLC determination of tramadol in human breast milk, J.  
 1192 Pharmaceut. Biomed., 32 (2003) 1061-1066.  
 1193

1194 [108] S.A. Barker, A.R. Long, C.R. Short, Isolation of drug residues from tissues by solid phase  
 1195 dispersion, J. Chromatogr. A, 475 (1989) 353-361.  
 1196

1197 [109] S.A. Barker, Matrix solid phase dispersion (MSPD), J. Biochem. Biophys. Methods, 70  
 1198 (2007) 151-162.

1199

1200 [110] J. Gañán, S. Morante-Zarcero, A. Gallego-Picó, R. María Garcinuño, P. Fernández-

1201 Hernando, I. Sierra, Evaluation of a molecularly imprinted polymer for determination of

1202 steroids in goat milk by matrix solid phase dispersion, *Talanta*, 126 (2014) 157-162.

1203

1204 [111] S. Nász, L. Debreczeni, T. Rikker, Z. Eke, Development and validation of a liquid

1205 chromatographic-tandem mass spectrometric method for determination of eleven coccidiostats

1206 in milk, *Food Chem.*, 133 (2012) 536-543.

1207

1208 [112] Q.-H. Zou, Y. Liu, M.-X. Xie, J. Han, L. Zhang, A rapid method for determination and

1209 confirmation of the thyreostats in milk and urine by matrix solid-phase dispersion and gas

1210 chromatography–mass spectrometry, *Anal. Chim. Acta*, 551 (2005) 184-191.

1211

1212 [113] G. Alberti, V. Amendola, M. Pesavento, R. Biesuz, Beyond the synthesis of novel solid

1213 phases: Review on modelling of sorption phenomena, *Coord. Chem. Rev.*, 256 (2012) 28-45.

1214

1215 [114] Y. Chen, Z. Guo, X. Wang, C. Qiu, Sample preparation, *J. Chromatogr. A*, 1184 (2008)

1216 191-219.

1217

1218 [115] J. Pawliszyn, Theory of solid-phase microextraction, *J. Chromatogr. Sci.*, 38 (2000) 270-

1219 278.

1220

1221 [116] H. Lord, J. Pawliszyn, Evolution of solid-phase microextraction technology, *J.*

1222 *Chromatogr. A*, 885 (2000) 153-193.

1223

1224 [117] H. Kataoka, K. Saito, Recent advances in SPME techniques in biomedical analysis, J.  
 1225 Pharmaceut. Biomed., 54 (2011) 926-950.  
 1226

1227 [118] N. Khodaei, A. Mehdinia, R. Esfandiarnejad, A. Jabbari, Ultra trace analysis of PAHs  
 1228 by designing simple injection of large amounts of analytes through the sample reconcentration  
 1229 on SPME fiber after magnetic solid phase extraction, Talanta, 147 (2016) 59-62.  
 1230

1231 [119] A. Spietelun, M. Pilarczyk, A. Kloskowski, J. Namiesnik, Current trends in solid-phase  
 1232 microextraction (SPME) fibre coatings, Chem. Soc. Rev., 39 (2010) 4524-4537.  
 1233

1234 [120] K. Kishida, Simplified extraction of tetracycline antibiotics from milk using a centrifugal  
 1235 ultrafiltration device, Food Chem., 126 (2011) 687-690.  
 1236

1237 [121] P.T. Männistö, R. Mäntylä, S. Nykänen, U. Lamminsivu, P. Ottoila, Impairing effect of  
 1238 food on ketoconazole absorption, Antimicrob. Agents Chemother., 21 (1982) 730-733.  
 1239

1240 [122] R. Padwal, R. Gabr, A. Sharma, L.-A. Langkaas, D. Birch, S. Karmali, D. Brocks, Effect  
 1241 of gastric bypass surgery on the absorption and bioavailability of metformin, Diabetes Care,  
 1242 34 (2011) 1295-1300.  
 1243

1244 [123] S.D. Ladas, P.E. Isaacs, G.M. Murphy, G.E. Sladen, Comparison of the effects of  
 1245 medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal  
 1246 function in normal man, Gut, 25 (1984) 405-411.  
 1247

1248 [124] D.R. Robertson, I. Higginson, B.S. Macklin, A.G. Renwick, D.G. Waller, C.F. George,  
1249 The influence of protein containing meals on the pharmacokinetics of levodopa in healthy  
1250 volunteers, Br. J. Clin. Pharmacol., 31 (1991) 413-417.

1251

1252 [125] P.E. Luner, D. VanDer Kamp, Wetting characteristics of media emulating gastric fluids,  
1253 Int. J. Pharm., 212 (2001) 81-91.

1254

1255 [126] H.D. Williams, K.P. Nott, D.A. Barrett, R. Ward, I.J. Hardy, C.D. Melia, Drug release  
1256 from HPMC matrices in milk and fat-rich emulsions, J. Pharm. Sci., 100 (2011) 4823-4835.

1257

1258

1259    **List of Tables**

1260    **Table 1.** Physicochemical Properties of the contents of the fed state stomach based on *in vivo*  
1261    measurements.

	Value	Technique employed	Meal	Sample	Reference
pH	6.23–6.84 (during meals and 1-2 hours after meal administration)	Bravo wireless pH monitoring capsule	No restriction in meal composition	11 volunteers (8 healthy)	[31]
	median 6.4– 2.7 (from 5 min to 3h 30min)	Aspiration through nasogastric tube	500 mL Ensure Plus®	20 healthy volunteers	[13]
	median 5.0 (peak 6.7)	Heidelberg capsule	Standard meal 1000 kcal	34 healthy volunteers	[28]
Osmolality	559 mOsm kg <sup>-1</sup> - 217 mOsm kg <sup>-1</sup> , (from 30 to 210 min)	Aspiration through nasogastric tube /freezing	500 mL Ensure Plus®	20 healthy volunteers	[13]

		point depression			
<b>Buffer capacity</b>	14-28 mmol L <sup>-1</sup> DpH (from 30 to 210 min)	Aspiration through nasogastric tube /titration with HCl	500 mL Ensure Plus®	20 healthy volunteers	[13]
<b>Surface tension</b>	30-31 mN m <sup>-1</sup>	Aspiration through nasogastric tube /titration with HCl	500 mL Ensure Plus®	20 healthy volunteers	[13]

1262

1263



1264 **Table 2.** Biopharmaceutics classification system, predictability of food effect and transporter  
 1265 effect [46, 48].

BCS class	Solubility/ permeability	Food effect	Drug examples	Transporter	
				effect on drug disposition	Transporter effect by high fat meal
I	+/+	no effect	Disopyramide  Ketoprofen  Verapamil	Minimal	No effect
II	-/+	+	Cyclosporine  Danazol  Dapsone	Efflux transporter effects predominate	Efflux transporters inhibition, intestinal drug solubilisation (drug passively absorbed)  Inhibition of both absorptive and efflux transporters. Food effect according to relative inhibition (drugs actively absorbed)
III	+/-	-	Fesofenadine  Nadolol  Valsartan	Absorptive transporter effect predominate	Inhibition of absorptive transporters in the intestine
IV	-/-	+, -,	Chlorothiazide  Furosemide	Possible substrates for both	All effects mentioned above for classes II and III

		no effect	Neomycin	absorptive and efflux transporters	
--	--	--------------	----------	--	--

1266

1267 **Table 3.** Examples of meals used in for the determination of drug- food interactions *in vivo*.

Meal	Composition	Fat content	Protein content	Carbohydrate content	Reference
<b>GSK high-fat standard meal</b>	2 slices of toasted white bread with butter, 2 eggs fried in butter, 2 slices of bacon, 2 ounces of hash browned (fried shredded) potatoes, 8 ounces of whole milk	67 g (603 kcal, 62% of total calories)	33 g (132 kcal, 14% of total calories)	58 g (232 kcal, 24% of total calories)	[43]
<b>FDA high-fat standard meal</b>	2 eggs fried in butter, 2 strips of bacon, 2 slices of toast with butter, 4 ounces of hash brown potatoes, 8 ounces of whole milk (800-1000 kcal)	500-600 kcal	150 kcal	250 kcal	[51]
<b>FDA intermediate-fat standard meal</b>	1 English muffin with butter, 1 fried egg, 1 slice of cheese, 1 slice Canadian bacon, 1 serving of hash browned (fried shredded potatoes), 6 ounces of orange juice, 8 ounces of whole milk	27 g, (240 kcal, 37 % of total calories)	29 g (116 kcal, 18% of total calories)	73 g (292 kcal, 45% of total calories)	[43]
<b>Light standardised breakfast</b>	Not specified (+100 mL of black coffee)	26 g	28 g	51 g	[121]

<b>Standardised high-carbohydrate meal</b>	Not specified (1000 kcal)	Not specified	Not specified	600 kcal	[122]
<b>Low-fat meal</b>	1 slice of white spread bread with jelly, 6 ounces of orange juice, 8 ounces of skim milk (250 kcal)	1 g	12 g	51 g	[83]
<b>Long chain triglyceride meal</b>	<p>Fat: 80% w/w medium chain triglycerides (C<sub>6</sub>-C<sub>12</sub>)</p> <p>Proteins: whey, casein and soy hydrolysates</p> <p>Carbohydrates: monosaccharides, oligosaccharides, polysaccharides</p>	36% of total calories	16% of total calories	48% of total calories	[123]
<b>Medium chain triglyceride meal</b>	<p>Fat: 31% w/w medium chain triglycerides (C<sub>6</sub>-C<sub>12</sub>)</p> <p>Proteins: whey, casein and soy hydrolysates</p> <p>Carbohydrates: monosaccharides, oligosaccharides, polysaccharides</p>	36% of total calories	16% of total calories	48% of total calories	[123]

<b>High-protein meal</b>	2% low fat milk, Carnation Instant Breakfast <sup>®</sup> and Pro Pac <sup>®</sup> Plus (protein supplement)	9 g	80 g	52 g	[53]
<b>High-protein meal</b>	Not specified (439.5 kcal)	17.1 g	30.5 g	43.5 g	[124]
<b>Low-protein meal</b>	Not specified (417.8 kcal)	14.9 g	10.5 g	64.3 g	[124]

1268

1269 <sup>a</sup> 25 °C

1270 <sup>b</sup> 37 °C

1271 \*Calories derived from fat

1272

1273

1274 **Table 4.** Physicochemical properties of gastric fed state biorelevant media used *in vitro*.

Medium	Mass (g)	Volume (mL)	Density (g/ mL)	pH	Buffer capacity (mEq pH <sup>-1</sup> L <sup>-1</sup> )	Osmolality (mOsmol kg <sup>-1</sup> )	Surface tension (mN m <sup>-1</sup> )	Viscosity (mPas)	Reference
<b>Standard breakfast (62% fat<sup>*</sup>)</b>	516± 6 <sup>a</sup>	474±7.7 <sup>a</sup>	1.09± 0.03 <sup>a</sup>	6.51± 0.01 <sup>a</sup> , 6.61± 0.03 <sup>b</sup>	29.3± 0.9 <sup>a</sup> , 30.1± 1.8 <sup>b</sup>	771± 10	52± 1 <sup>a</sup> , 44± 1 <sup>b</sup>		[43]
<b>Standard breakfast (37% fat<sup>*</sup>)</b>	540± 5.5 <sup>a</sup>	513± 7.3 <sup>a</sup>	1.05± 0.03 <sup>a</sup>	5.28± 0.03 <sup>a</sup> , 5.12± 0.04 <sup>b</sup>	49.6± 1.7 <sup>a</sup> , 47.2± 1.5 <sup>b</sup>	713± 10	49± 1 <sup>a</sup> , 45± 1 <sup>b</sup>		[43]
<b>Milk (48.1% fat<sup>*</sup>)</b>			1.03± 0.005 <sup>a</sup>	6.72± 0.02 <sup>a</sup> , 6.63± 0.01 <sup>b</sup>	14.4± 0.2 <sup>a</sup> , 13.9± 0.2 <sup>b</sup>	285± 2.7	54.2± 0.4 <sup>a</sup> , 49.8± 0.6 <sup>b</sup>	1.9± 0.04 <sup>a</sup> ,	[43]

								1.5± 0.04 <sup>b</sup>	
<b>Partially digested milk (i. 3.5% fat milk, ii. milk + HCl + pepsin, iii. Milk + HCl + pepsin + lipase)</b>				i. 6.5, ii. 4.7-2.6 (in 6 h), iii. 5.1-4 (in 6h)	i. 13-19 ii. 19-38 iii. 47-69	i. 260, ii. 338-462, iii. 475-540			[44]
<b>Ensure<sup>®</sup> (30.1% fat)</b>			1.04± 0.016 <sup>a</sup>	6.68± 0.01 <sup>a</sup> , 6.58± 0.1 <sup>b</sup>	15.4± 0.1 <sup>a</sup> , 16.4 <sup>b</sup>	375± 3.5	50.5± 0.2 <sup>a</sup> , 47.8± 0.1 <sup>b</sup>	6.3± 0.09 <sup>a</sup> , 4.4± 0.07 <sup>b</sup>	[43]
<b>Ensure Plus<sup>®</sup> (29.1% fat)</b>			1.08± 0.003 <sup>a</sup>	6.62± 0.03 <sup>a</sup> , 6.45± 0.02 <sup>b</sup>	20± 0.7 <sup>a</sup> , 21± 0.3 <sup>b</sup>	730± 10	53.2± 0.2 <sup>a</sup> , 48.4± 0.1 <sup>b</sup>	19.1± 0.1 <sup>a</sup> , 12.3± 0.1 <sup>b</sup>	[43]
<b>Early FeSSGF (milk based)</b>				6.4	21.33	559			[37]

<b>Middle FeSSGF (milk based)</b>				5	25	400			[37]
<b>Late FeSSGF (milk based)</b>				3	25	300			[37]
<b>Early FeSSGF (Lipofundin® based)</b>				6.4	21	559			[66]
<b>Middle FeSSGF (Lipofundin® based)</b>				5	25	400			[66]
<b>Late FeSSGF (Lipofundin® based)</b>				3	25	300			[66]
<b>Nutrison®</b>				5.4		420			[5]
<b>FSGES</b>				5					[125]



1275

1276

<b>Intralipid®</b>						320		2.7± 0.06	[126]
<b>30%</b>									

1277 **Table 5.** Composition of nutrient drinks/parenteral emulsions used as fed state gastric media  
 1278 in *vitro*.

Nutrient drink	Composition (per Litre) <sup>†</sup>
Scandishake <sup>®</sup> mix	598 kcal, 30.4 g fat, 11.7 g protein, 69.5 g carbohydrate <sup>††</sup>
Ensure <sup>®</sup>	930 kcal, 25 g fat, 38 g protein, 135 g carbohydrate
Ensure Plus <sup>®</sup>	1500 kcal, 46 g fat, 55 g protein, 210 g carbohydrate
Nutrison <sup>®</sup>	1000 kcal, 39 g fat, 40 g protein, 123 g carbohydrate
Intralipid <sup>®</sup> 30	3000 kcal, 300 g fat

1279

1280 <sup>†</sup> according to the manufacturer [63] (Ensure<sup>®</sup> and Ensure Plus<sup>®</sup> vanilla flavour)

1281 <sup>††</sup> 85 g powder in 240 mL whole milk

1282

1283 **Figure captions**

1284 **Figure 1:** mean pH values from aspirates of patients after administration of 500 mL Ensure  
1285 Plus® containing 10 mg/mL PEG 4000. (data extracted from [13])


1286 **Figure 2.** Schematic representation demonstrating the lipid digestion, formation of micelles  
1287 and drug absorption in the small intestine after administration of a meal; processes taking place  
1288 in the stomach in the highlighted rectangle. (modified from [22])

1289 **Figure 3.** Pharmacokinetic parameters after administration of two 100 mg itraconazole  
1290 capsules under fasted and fed (standard breakfast) state conditions. \* denotes statistically  
1291 significant difference ( $p < 0.001$ , multivariate ANOVA). (data extracted from [68])

1292

1293

1294




1295

1296


1297

1298



1299

1300



1301